Home > Result Summaries: Compounds > fosamprenavir > Result Summary for ESS40001

Result Summary for ESS40001

Result Summary

Protocol ID:	ESS40001
Clinical Study ID:	ESS40001
Official Title:	A Phase II, Open-Label, Randomized Study to Compare the Efficacy and Safety of EPIVIR/ZIAGEN/Zerit (3TC/ABC/d4T) Versus EPIVIR/ZIAGEN/Sustiva (3TC/ABC/EFV) Versus EPIVIR/ZIAGEN/GW433908/Norvir (3TC/ABC/908/RTV) for 96 Weeks in the Treatment of HIV-1 Infected Subjects Who are Antiretroviral Thera ...
Phase:	Phase 2
Study Indications or Diseases:	Infection, Human Immunodeficiency Virus I
Generic Name:	fosamprenavir
Trade/Product Name:	lexiva
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Bartlett JA, Johnson J, Herrera G, Sosa N, Rodriguez A, Liao Q, Griffith S, Irlbeck D, and Shaefer MS for the Clinically Significant Long-Term Antiretroviral Sequential Sequencing (CLASS) Study Team; Long Term Results of Initial Therapy with Abacavir and Lamivudine Combined with Efavirenz, Amprenavir/Ritonavir or Stavudine: 96 Week Results from the CLASS Study; J Acquir Immune Defic Syndr; Volume 43, Number 2, November 1, 2006.